SARATOGA, Calif., March 17 /PRNewswire/ -- VisionCare Ophthalmic
Technologies, Inc., a developer of advanced visual prosthetic devices for the
treatment of age-related macular degeneration (AMD), announced today three
presentations on its platform technology are scheduled at the upcoming annual
symposium of the American Society of Cataract and Refractive Surgery (ASCRS)
March 18 - 21, 2006, in San Francisco. Podium presentations are scheduled at
the Moscone Convention Center as follows:
Clinical Trial Presentations
-- Saturday, March 18, 1:07 PM, Moscone Room 301
Implantable Miniature Telescope in Patients with ARMD: Final
Assessment of Surgical Technique from the Phase II/III Trial
Mark Packer, MD
-- Monday, March 20, 1:32 PM, Moscone Room 110
Implantable Miniature Telescope in Patients with Macular
Degeneration: 1-Year Results
R. Doyle Stulting, MD, PhD
Preclinical Study Presentation
-- Saturday, March 18, 1:02 PM, Moscone Room 301
Preclinical Studies of Implantable Miniature Telescope for
Ehud I. Assia, MD
At ASCRS, VisionCare is located in Booth #3139 at the Moscone Convention
Center in San Francisco.
About the Visual Prosthetic Device
The investigational Implantable Miniature Telescope (IMT(TM) by Dr. Isaac
Lipshitz) is designed to be a permanent solution for moderate to profound
vision loss due to advanced, end-stage forms of AMD that have no current
surgical or medical treatment options. Smaller than a pea, the telescope
prosthetic device is implanted in one eye in an outpatient surgical procedure.
In the implanted eye, the device renders enlarged central vision images over a
wide area of the retina to improve central vision, while the non-operated eye
provides peripheral vision for mobility and orientation.
The prospective IMT002 Phase II/III trial, evaluating the safety and
efficacy of VisionCare's investigational device in individuals with moderate
to profound bilateral central vision impairment associated with end-stage AMD,
is complete. The trial enrolled over 200 patients at 28 leading medical
universities and ophthalmic centers across the country. VisionCare has
submitted a Premarket Approval (PMA) Application which seeks regulatory
approval for the telescope prosthetic device to treat central vision loss due
to advanced, irreversible forms of AMD. The Food and Drug Administration (FDA)
has assigned the application expedited review status.
About Macular Degeneration
Macular degeneration is a disorder of the central retina, or macula, which
is responsible for detailed vision that controls important functional visual
activities like reading, recognizing faces, and watching television. According
to the National Eye Institute over 1.7 million Americans over age 50 suffer
mild to profound vision loss from advanced AMD, which culminates as end-stage
AMD. Approximately half of the individuals living with advanced AMD are
affected in both eyes.
VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA is
a privately-held company focused on development, manufacturing, and marketing
of visual prosthetic devices. The Implantable Miniature Telescope was invented
by company founders, Isaac Lipshitz, M.D. and Yossi Gross. Information on
VisionCare can be found at www.visioncareinc.net.
SOURCE VisionCare Ophthalmic Technologies, Inc.